Back to results
US 2015/0376239 A1Published application
Use of p3 of bacteriophage fusion proteins as amyloid binding agents
AssigneeNeuroPhage Pharmaceuticals, Inc.
InventorsRajaraman Krishnan, Richard Fisher
Life of this patent
Estimating the term…
Abstract
The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.
Claims19
1-53. (canceled)
A fusion protein comprising an amyloid binding fragment of g3p and an Fc fragment of an immunoglobulin, wherein the protein comprises an amino acid sequence selected from:
- (a) amino acids 21-506 of SEQ ID NO:9;
- (b) amino acids 22-506 of SEQ ID NO:9;
- (c) amino acids 23-506 of SEQ ID NO:9;
- (d) amino acids 21-505 of SEQ ID NO:9;
- (e) amino acids 22-505 of SEQ ID NO:9;
- (f) amino acids 23-505 of SEQ ID NO:9;
- (g) amino acids 21-506 of SEQ ID NO:11;
- (h) amino acids 22-506 of SEQ ID NO:11;
- (i) amino acids 23-506 of SEQ ID NO:11;
- (j) amino acids 21-505 of SEQ ID NO:11;
- (k) amino acids 22-505 of SEQ ID NO:11;
- (l) amino acids 23-505 of SEQ ID NO:11;
- (m) amino acids 21-509 of SEQ ID NO:13;
- (n) amino acids 22-509 of SEQ ID NO:13;
- (o) amino acids 23-509 of SEQ ID NO:13;
- (p) amino acids 21-508 of SEQ ID NO:13;
- (q) amino acids 22-508 of SEQ ID NO:13;
- (r) amino acids 23-508 of SEQ ID NO:13;
- (s) amino acids 21-528 of SEQ ID NO:31;
- (t) amino acids 22-528 of SEQ ID NO:31;
- (u) amino acids 23-528 of SEQ ID NO:31;
- (v) amino acids 21-527 of SEQ ID NO:31;
- (w) amino acids 22-527 of SEQ ID NO:31;
- (x) amino acids 23-527 of SEQ ID NO:31;
- and
- (y) a mutant or variant that is at least 95% identical to the amino acid sequence of any one of (a)-(x) and is capable of binding to amyloid.
23 more elements
Dependencies are inferred from the claim text.